By Dean Seal
Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong.
The medical-technology company posted a profit of $385.6 million, or 65 cents a share, up from $369.9 million, or 61 cents a share, in the same quarter a year ago.
Stripping out one-time items, adjusted earnings were 59 cents a share. Analysts polled by Factset had been expecting 55 cents a share.
Sales jumped 9% to $1.39 billion, topping analyst projections for $1.36 billion, according to FactSet.
The Irvine, Calif., company said the top-line growth was driven by strong demand for its transcatheter aortic valve replacements and repair and replacement technologies for both mitral and tricuspid valves.
For the first quarter of 2025, the company expects adjusted earnings of 58 cents to 64 cents a share on $1.35 billion to $1.43 billion in revenue. That's in line with analyst views for adjusted earnings of 59 cents a share on $1.41 billion in revenue.
The stock rose 6.7% to $75.69 in postmarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 11, 2025 17:07 ET (22:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。